AtriCure Inc. (NASDAQ:ATRC)’s share price shot up 3.1% on Tuesday . The company traded as high as $14.63 and last traded at $14.48, with a volume of 173,192 shares traded. The stock had previously closed at $14.05.

A number of brokerages have recently weighed in on ATRC. Needham & Company LLC reissued a “buy” rating and set a $20.00 price target (down from $23.00) on shares of AtriCure in a research report on Monday. Piper Jaffray Cos. reissued an “overweight” rating and set a $17.00 price target (down from $22.00) on shares of AtriCure in a research report on Monday. Canaccord Genuity set a $21.00 price target on shares of AtriCure and gave the stock a “buy” rating in a research report on Saturday. JMP Securities set a $23.00 price target on shares of AtriCure and gave the stock a “buy” rating in a research report on Saturday. Finally, Stifel Nicolaus dropped their price objective on shares of AtriCure from $26.00 to $21.00 and set a “buy” rating on the stock in a report on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $21.25.

The stock’s 50 day moving average is $14.90 and its 200 day moving average is $15.84. The firm’s market cap is $458.47 million.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Thursday, August 4th. The medical device company reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.30) by $0.04. The business earned $39.70 million during the quarter, compared to analyst estimates of $39.84 million. The company’s revenue was up 21.8% compared to the same quarter last year. During the same quarter last year, the company posted ($0.18) earnings per share. Equities research analysts anticipate that AtriCure Inc. will post ($1.16) earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the stock. Victory Capital Management Inc. raised its stake in AtriCure by 15.3% in the fourth quarter. Victory Capital Management Inc. now owns 51,647 shares of the medical device company’s stock worth $1,159,000 after buying an additional 6,845 shares in the last quarter. Wells Fargo & Company MN raised its stake in AtriCure by 20.2% in the fourth quarter. Wells Fargo & Company MN now owns 659,070 shares of the medical device company’s stock worth $14,789,000 after buying an additional 110,890 shares in the last quarter. Paradigm Capital Management Inc. NY raised its stake in AtriCure by 108.3% in the fourth quarter. Paradigm Capital Management Inc. NY now owns 247,525 shares of the medical device company’s stock worth $5,554,000 after buying an additional 128,700 shares in the last quarter. Finally, RS Investment Management Co. LLC raised its stake in AtriCure by 21.1% in the fourth quarter. RS Investment Management Co. LLC now owns 2,679,551 shares of the medical device company’s stock worth $60,129,000 after buying an additional 466,200 shares in the last quarter.

AtriCure, Inc is a medical device company providing atrial fibrillation (Afib) solutions. The Company’s segment develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. The Company has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.